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Abstract
One source of bacteria that has not been widely explored is lactic acid bacteria originating from honeycomb (hive).
Timor Island has a wealth of giant honey bees (Apis dorsata). Lactic acid bacteria from the Apis dorsata hive in Timor
Island need to be investigated to obtain probiotic candidates with specific functional properties. Lactic acid bacteria
were isolated from honeycomb by using de Mann, Rogosa, and Sharpe agar supplemented with 1% of CaCO3. Bacterial
isolates that formed clear zones and were Gram-positive and catalase-negative were determined as lactic acid bacteria.
The probiotic candidates are isolates that are resistant to bile salts and low pH; susceptible to antibiotics; are able to
aggregate, autoaggregate, and coaggregate; and have antibacterial activities. Isolate MC7 was selected as a probiotic
candidate and had inhibitory activity against angiotensin-converting enzyme (ACE) with IC50 263,098 ppm. Isolate
MC7 showed weak inhibition against ɑ-glucosidase activity. Molecular identification based on 16S rRNA gene showed
that MC7 isolate was closely related to Lactobacillus rhamnosus with 100% similarity. Therefore, isolate MC7 was
recommended as a probiotic candidate with a functional property as an inhibitor of ACE.
Keywords: angiotensin-converting enzyme, Apis dorsata, hive, lactic acid bacteria, probiotic

results in a hypertensive condition. ACE also plays a
role in activating bradykinin, a vasodilator peptide.
Inhibition of ACE can decrease blood pressure in the
body; this principle can be used to decrease the high
blood pressure of patients with hypertension.

Introduction
Some lactic acid bacteria have an important role in
maintaining human health and as probiotics. Probiotic
bacteria can improve the human immune system, reduce
cholesterol, ease lactose intolerance and allergies, and
improve intestinal microbiota, as well as have anticancer
and antidiarrhea properties [1-3]. Desirable probiotic
properties that can be determined by in vitro tests are
resistance to acids and bile salts, adhesion to the host’s
intestinal surface, ability to eliminate pathogens or reduce
pathogenic adhesion, ability to produce substances that
have an antagonistic effect on pathogens, and bile salt
hydrolase activity [1].

Some probiotic bacteria have functional properties as
inhibitor of ɑ-glucosidase. Lactobacillus rhamnosus, L.
casei, and L. bulgaricus have been known to produce
exo-polysaccharides which can inhibit ɑ-glucosidase
enzyme [7], an enzyme found on the surface of the
small intestine, and its function is to catalyze carbohydrate digestion. Inhibition of ɑ-glucosidase activity can
reduce blood glucose levels. This principle has been
used in the production of antidiabetic compounds such
as acarbose, which can be used by people with type-2
diabetes mellitus to reduce blood glucose levels.

Some probiotic bacteria have functional properties as
inhibitors of angiotensin-converting enzyme (ACE).
Lactobacillus plantarum, L. spp., L. sakei and L. curvatus
are probiotics that produce extracellular peptide
compounds that can inhibit ACE [4-6]. ACE is a
dipeptidyl carboxy peptidase that catalyzes the reaction
in which angiotensin I changes to angiotensin II, which

Common sources of lactic acid bacteria are milk and
dairy products, animal digestive tracts, and plants.
Another source of lactic acid bacteria is honeycomb
(hive). Lactobacillus sp. Firm5, L. spp., and L. kunkeei
50
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have been isolated from the Apis mellifera honeycomb
in Tucson, an arid region in the USA [8]. Lactobacillus
kunkeei YH-15, L. sp. Bma5 LMG P-24090, and L. sp.
Taj Mustafa-1 UPMC 431 have been isolated from an
Apis dorsata hive in Kedah, a tropical climate region in
Malaysia [9]. Little information is known about the
potential probiotic properties of lactic acid bacteria from
honeycomb.

Kirby-Bauer method. Amoxicillin and thiamphenicol
were used in the susceptibility test. Inhibition zone
criteria were determined based on the following criteria:
sensitive (inhibition zone diameter >12 mm),
intermediate (inhibition zone diameter between 5-12
mm), and resistance (inhibition zone diameter ≤4 mm)
[15]. Lactobacillus rhamnosus R23, a probiotic with
antidiarrhea property [16], was used as control.

Timor Island, a tropical savanna climate region, has a
considerable wealth of honey bee resources, especially
giant honey bees (Apis dorsata). Previous research
found that the Apis dorsata hive from Timor Island
contained lactic acid bacteria such as Lactobacillus
kunkeei strain YH-15 and Lactococcus lactis subsp.
tructae strain L105 [10]. Exploration of lactic acid
bacteria from Apis dorsata hive needs to be conducted
to find a probiotic candidate that can produce inhibitor
metabolites such as inhibitor of ACE or ɑ-glucosidase.

Aggregation, autoaggregation, and coaggregation
test. For the aggregation test, lactic acid bacteria isolates
were cultured in MRS broth and incubated at 37 °C for
48 hours [17]. Positive aggregation can be detected
from the precipitation of cell bacteria at the bottom of
the tube and a clear supernatant. Lactic acid bacteria
were tested by autoaggregation methods [18, 19].
Autoaggregation percentage can be calculated by the
following formula:

Materials and Methods
Isolation of lactic acid bacteria from Apis dorsata
hives in Kupang. Apis dorsata hives and flowers were
collected from Kupang. The lactic acid bacteria were
isolated from hives by using de Mann, Rogosa, and
Sharpe (MRS) [7] agar supplemented with 1% CaCO3,
according to Prasirtsak et al. [11]. Isolates that formed a
clear zone were characterized with Gram staining and
catalase test. The isolated bacteria were stained by
Gram staining method [12] and tested for the presence
of catalase [13]. The isolates that formed a clear zone in
MRS supplemented with CaCO3 and were Gram-positive
and catalase-negative were determined as lactic acid
bacteria. The lactic acid bacteria were maintained in
MRS broth supplemented with 40% glycerol and then
stored in a freezer. The isolates were deposited in IPB
Culture Collection (IPBCC) with collection number
IPBCC b 20 1557 (MA15), IPBCC b 20 1558 (MC1),
and IPBCC b 20 1559 (MC7).
Isolates’ tolerance to bile salts and low pH. The
isolates’ tolerance to bile salts and low pH was
evaluated by total plate count methods [7, 14]. The
isolates were cultured for 18 hours in MRS broth at 37
°C. To determine tolerance to bile salts, 100 μL of the
culture was inoculated in MRS broth supplemented by
0.3% (w/v) bile salts (Himedia, India), then incubated at
37 °C for 6 hours. Tolerance to low pH was assayed by
inoculating 100 μL of bacterial suspension in MRS
broth with pH 3 and then incubating it for 3 hours at 37
°C. The ability to tolerate the bile salts and low pH was
determined based on the log number difference of
colonies between MRS containing bile salts/low pH and
MRS only.
Antibiotic susceptibility test. The susceptibility of
lactic acid bacteria to antibiotics was tested by using the
Makara J. Sci.

Autoaggregation (%) = 1 － (At/A0) ×100

(1)

where At represents an absorbance of 5 hours at 600 nm,
and A0 represents an absorbance of 0 hours at 600 nm.
Lactobacillus rhamnosus R23 was used as control. The
isolate’s ability to coaggregate with pathogens was
evaluated by conducting a coaggregation test [20] that
involved three pathogenic bacteria (Escherichia coli
ATCC 25922, S. aureus ATCC 25923, S. typhymurium
ATCC 14028). The percentage of coaggregation can be
calculated as follows:
Coaggregation (%) = {[(Abspat+Abslab)/2]－Absmix}/
[Abspat+Abslab)/2] ×100
(2)
where Abspat is the absorbance of pathogen, Abslab is the
absorbance of lactic acid bacteria, and Absmix is the
absorbance of a mixture pathogen and lactic acid
bacteria. L. rhamnosus R23 was used as control.
Hydrophobicity test. The hydrophobicity of lactic acid
bacteria was tested by using microbial adhesion to
solvent or MATS [17]. The hydrophobicity of the cell
surface of lactic acid bacteria was calculated by the
following equation:
H (%) = (A－A0)/A × 100

(3)

where H is the hydrophobicity, A is the absorbance after
1 hour at 600 nm, and A0 is the absorbance of 0 hours at
600 nm. Lactobacillus rhamnosus R23, a probiotic with
antidiarrhea properties [13], was used as culture
reference.
Antibacterial activity test. Lactic acid bacteria were
grown in MRS broth for 48 hours, and then the
supernatant was collected by centrifuging. The
antibacterial activity of supernatant and neutralized
supernatant was determined using agar well diffusion
March 2020  Vol. 24  No. 1
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method [21]. Three pathogen bacteria (Escherichia coli
ATCC 25922, S. aureus ATCC 25923, S. typhymurium
ATCC 14028) were obtained from the Laboratorium of
Food Science (IPB University) and used in the antibacterial test. Lactobacillus rhamnosus R23, a probiotic
with antidiarrhea properties [16], was used as control.
Identification of lactic acid bacteria. DNA extraction
was performed from the bacterial cells by using PrestoTM
Mini gDNA Bacteria Kit (Geneaid, Taiwan). 16S rRNA
genes were amplified by Polymerase Chain Reaction
(PCR) by using primer pairs 63F and 1387R [22]. DNA
products were sent to the 1st Base DNA Sequencing
Division (Apical Scientific Sequencing) for sequencing.
The obtained DNA sequences were analyzed by
performimg EzTaxon Biocloud [23]. The phylogenetic
tree was analyzed by MEGA 7.0 [24] with neighbor
joining method and 2000 bootstrap replications.
ACE inhibitor test. Lactic acid bacteria were cultured
in MRS broth for 48 hours and then centrifuged. The
supernatant was evaporated and then freeze dried. The
freeze-dried supernatant was diluted in sterile water at
different concentrations and used for ACE inhibitor
measurement. Inhibitor activity against ACE was
measured by using spectrophotometer method based on
the reaction of enzyme and substrate [25]. Substrate
hippuryl-histidyl-leucine was hydrolyzed by ACE to
become hypuric acid. The release of hypuric acid was
determined based on the absorbance value at 492 nm.
The inhibition of ACE was calculated by the following
formula:
ACE inhibitory activity (%) = (BA)/(BC) × 100

(4)

where A is the absorbance of the sample, B is the
absorbance of the control, and C is the absorbance of
the blank. Captopril was used as positive control. A
high absorbance value of a sample indicates that more
hypuric acid products are formed. This finding jndicates
low sample inhibitory activity against ACE. IC50 was
determined using a regression formula.
-glucosidase inhibitor test. Sample preparation was
performed similarly to the evaluation of the ACE
inhibitor. Inhibitor ɑ-glucosidase test was evaluated
using spectrophotometer method [26]. Substrate pNitrophenyl-ɑ-D-glucopyranoside was hydrolyzed by ɑglucosidase to p-Nitrophenol. Acarbose (Bayer) was
used as positive control. The inhibition of ɑ-glucosidase
was determined by using the following formula:
Inhibition (%) = [(Ac－As)/Ac] × 100

(5)

where Ac is the absorbance of the control and As is the
absorbance of the sample. The absorbance value of the
sample showed a number of p-Nitrophenol products as a
result of substrate hydrolysis. High sample absorbance
indicates more p-Nitrophenol products and lower
inhibitory activity against ɑ-glucosidase.
Makara J. Sci.

Results and Discussion
Isolation of lactic acid bacteria. A total of 135 isolates
formed clear zones on the MRS agar supplemented by
1% CaCO3, but only 81 isolates were Gram-positive and
did not have catalase. Therefore, 81 isolates were
determined as lactic acid bacteria isolates. Lactic acid
bacteria inoculated on MRS agar supplemented with 1%
CaCO3 formed clear zones. Lactic acid that was
produced by the lactic acid bacteria fermentation reacts
with CaCO3 to form calcium lactate. The clear zone
around the colony of lactic acid bacteria indicates the
presence of a water-soluble calcium-lactic compound.
Isolates’ tolerance to bile salts and low pH. All
isolates can grow on MRS agar supplemented with 0.3
% bile salts (Himedia). Ten isolates were selected as
tolerant isolates to bile salts and low pH. Three of 10
isolates of lactic acid bacteria were selected as the best
isolates on the basis of their tolerance (Figure 1). The
three isolates were MA15, MC1, and MC7 and they can
grow in MRS supplemented with bile salts that had a
similar condition as the human intestine and in media
with low pH such as the human gastric juice. This
condition is important in enabling the three isolates to
pass through the digestive tract. Bile salts are harmful to
bacteria cells because they can damage the structure of
the cell membrane [7]. The average concentration of
bile salts in the human intestine is 0.3% (w/v) [27].
MA15, MC1 and MC7 can grow in MRS supplemented
with 0.3% (w/v) bile salts and are thus tolerant to bile
salts in the human intestine. The human stomach has
low pH (2.53.5), and food travels through the stomach
for 24 hours [28]. The 29 Lactobacillus strains of dairy
origin were able to survive at pH 3.0 [29]. Lactobacillus
reuteri, L. rhamnosus G5435, L. acidophilus 388, and L.
delbrueckii subsp. bulgaricus 11842 can survive during
simulated gastric transit at pH 3 for 3 hours [30]. The
three isolates from Apis dorsata hives can survive in
MRS with pH 3.0, thereby suggesting that the isolates
can pass through and enter the human intestine.
Antibiotic susceptibility test. The three isolates of lactic
acid bacteria and Lactobacillus rhamnosus R23 (as
control) are susceptible to amoxicillin and thiamphenicol.
The inhibiton zone diameter of antibiotics toward the
three lactic acid bacteria and positive control ranges
from 21 mm to 28 mm (Table 1), thus indicating that the
bacteria are sensitive to antibiotics. Moreover, the
bacteria are more sensitive to amoxicillin than to
thiamphenicol. The control bacterium is more sensitive
than the three lactic acid bacteria. The three lactic acid
bacteria isolates are sensitive to amoxicillin and
thiamphenicol. The sensitivity of bacteria to antibiotics
is important in selecting probiotics because these
properties prevent the bacteria from transferring
resistant genes to pathogenic bacteria. Resistant bacteria
can transfer resistant properties to other bacteria through
March 2020  Vol. 24  No. 1
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horizontal gene transfer [31]. The three mechanisms of
horizontal gene transfer are transformation, conjugation,
and transduction. Transformation is a gene transfer
process in which cells take up free DNA directly from
their environment, and then the DNA is derived from a
donor bacterium and taken up by a recipient bacterium
[32]. Plasmid or other self-transmissible DNA elements
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transfer themselves and sometimes other DNA into
another bacterial cell in a process called conjugation
[32]. Bacteriophages sometimes transfer bacterial DNA
from one cell to another in a process called transduction,
in which a phage carries DNA from one bacterium to
another [32].

Table 1. Results of Antibiotic Susceptibility Test

Isolate
MA15
MC1
MC7
LrR23

Amoxicillin (25 μg/mL)
Inhibition zone (mm)
Criteriaa
25
sensitive
22
sensitive
27
sensitive
28
sensitive

Thiamphenicol (30 μg/mL)
Inhibition zone (mm)
Criteriaa
24
sensitive
21
sensitive
25
sensitive
25
sensitive

a

Based on the criteria of Mukherjee (1988), i.e., sensitive (diameter of inhibition zone >12 mm), intermediate
(diameter of inhibition zone between 5－12 mm), and resistance (diameter of inhibition zone ≤4 mm).
Table 2. Result of Aggregation, Autoaggregation and Coaggregation Test

Isolate

Aggregation

Autoaggregatio
n (%)

MA15
MC1
MC7
LrR23

+
+
+
+

91.2
88.4
91.9
95.6

a

Coaggregation (%) with pathogen
E. coli
S. aureus
S. typhymurium
90.47
92.30
92.00
-13.33b
88.57
76.47
-56.09b
95.65
86.66
b
-26.67
80.00
89.47

a

Positive aggregation is found if sediment-like sands formed on the bottom of the tube and the upper layer of
the supernatant is clear. bNegative values indicate no coaggregation activity.
Table 3. Hydrophobicity Properties of Lactic Acid Bacteria

Isolate
MA15
MC1
MC7
LrR23

Hydrophobicity (%)
8.17
3.66
8.93
11.5

a

Criteria
Not hydrophobic
Not hydrophobic
Not hydrophobic
Not hydrophobic

Note: aHydrophobicity criteria according to Santos et al. (1990): hydrophobicity >50% (strongly hydrophobic), hydrophobycity of 20－50% (moderately hydrophobic), hydrophobicity <20% (not hydrophobic).
Table 4. Results of Antibacterial Test of Lactic Acid Bacterial Supernatant

Isolate
MA15
MC1
MC7
LrR23

a
15
7
17
26

S. aureus
b
13
8
15
25

Diameter of inhibition zone (mm)
S. typhymurium
E.coli
a
b
a
b
9
10
9
11
9
10
8
11
10
11
10
11
13
13
22
13

Notes: a = supernatant; b = neutralized supernatant.
Table 5. Identification of Lactic Acid Bacteria Based on 16S rDNA Sequence Data

Isolate
MA15
MC1
MC7
Makara J. Sci.

Species
Enterococcus durans
Enterococcus durans
Lactobacillus rhamnosus

Strain
NBRC 100479
NBRC 100479
JCM 1136

Similarity (%)
99.91
99.91
100.00

Accession number
BCQB 01000108
BCQB 01000108
BALT 01000058
March 2020  Vol. 24  No. 1
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Figure 1. Selection of Lactic Acid Bacteria Based on the Test Result of Resistance to Bile Salts and Low pH. Three Isolates
(MA15, MC1, MC7) were Selected as Bacteria that are Resistant to Bile Salts and Low pH.

(a)

(b)
Figure 2. (a) Inhibition of Lactic Acid Bacteria Supernatant and Captopril against ACE; (b) Inhibition of Lactic Acid
Bacteria Supernatant and Acarbose against -glucosidase

Makara J. Sci.
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Aggregation, autoaggregation and coaggregation
test. The percentage of autoaggregation was between
88.4% and 95.6% (Table 2). The percentage of
coaggregation between the three lactic acid bacteria
isolates and two pathogen bacteria was high (Table 2).
The lactic acid bacteria formed an aggregate with
Staphylococcus aureus and Salmonella thyphymurium.
The autoaggregation percentage correlates to the ability
of the lactic acid bacteria to form aggregate among the
cells of lactic acid bacteria. The ability of lactic acid
bacteria to form aggregation and autoaggregation is
necessary for the adherence of lactic acid bacteria to the
surface of intestine walls [19]. Coaggregation between
lactic acid bacteria and pathogen can inhibit pathogens
from adhering to the surface of intestine walls.
Therefore, the host could not be infected by pathogens
because the pathogens were eliminated by the lactic acid
bacteria. The high coaggregation ability of the isolates
against pathogen can prevent pathogens from attaching
to the host epithelial tissue [19]. These abilities are
important in supporting the adherence of lactic acid
bacteria on the surface of the intestinal wall.
Hydrophobicity test. The selected isolates (MA15,
MC1, MC7) and L. rhamnosus R23 are not hydrophobic.
These results are consistent with the results from
previous research, which stated that L. rhamnosus R23
as a probiotic candidate is not hydrophobic or
hydrophilic [18]. Although hydrophilic, L. rhamnosus
R23 can adhere to the surface of rat intestinal
epithelium [18]. The adhesive ability of Lactobacilli is
not dependent on hydrophobicity and no correlation
exists between the hydrophobicity of the cell surface
and adhesive ability [18]. Therefore, the hydrophylic
properties of bacteria do not affect the ability of bacteria
to adhere to the surface of the human intestine. This fact
is supported by probiotics such as L. acidophylus LA1,
L. casei Shirota, and Lactobacillus rhamnosus GG which
had been proved to deliver beneficial health effects
despite their low adhesive properties (3.212.6%) [17].
Antibacterial activity test. The supernatant of MC1,
MC7, and MA15 exhibited antibacterial activity against
pathogen bacteria (Table 4). The antibacterial activity of
the control (L. rhamnosus R23) was higher than that of
others. L. rhamnosus R23 possessed broad-spectrum
antibacterial activity that can inhibit Gram-positive and
Gram-negative bacteria. MA15, MC1, and MC7 also
showed a broad-spectrum antibacterial activity, but it
was lower than that of the control. The supernatant of
lactic acid bacteria (MA15, MC1, MC7) showed
antibacterial activity against pathogen bacteria.
Therefore, the three isolates are expected to be able to
eliminate pathogens from the human digestive tract. The
lactic acid bacteria can decrease pH in MRS broth
because the bacteria produce lactic acid, which can
inhibit the three pathogen bacteria (Escherichia coli
ATCC 25922, S. aureus ATCC 25923, S. typhymurium
Makara J. Sci.
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ATCC 14028). The neutralized supernatant showed
antibacterial activity against pathogenic bacteria,
thereby indicating that the supernatant contained
antibacterial compounds other than acid. This result was
in agreement with that of a previous study [16], L.
rhamnosus R23 has antibacterial activity against E. coli
K1.1 (enteropathogenic bacteria that cause diarhea).
Daily administration of L. rhamnosus R23 protected the
mice from diarrhea even though they were infected by
E. coli K1.1 [16].
Identification of lactic acid bacteria. The lactic acid
bacteria, MA15, and MC1 isolates were closely related
to Enterococcus durans with 99.91% similarity as
indicated by molecular identification based on 16S
rDNA sequence data (Table 5), whereas the MC7
isolate was closely related to Lactobacillus rhamnosus
with 100% similarity. The three isolates of lactic acid
bacteria were registered in GenBank (accession number
MH656781 [MA15], MH656782 [MC1], and MH656783
[MC7]). MA15 and MC1 isolates are closely related to
Enterococcus durans NBRC 100479. Both MA15 and
MC1 share the same genus with the pathogens
Enterococcus faecalis and Enterococcus faecium, which
cause enterococcal endocarditis in humans [34]. E.
durans is non-faecalis enterococci found in the
intestines of animals [34]. These bacteria rarely
endocarditis in humans. Enterococcus durans EP1 has
been recommended as a probiotic with antiinflammation
properties [35]. E. durans EP1 is not virulence, sensitive
to vancomycin, and non-ɑ-hemolytic [35].
ACE inhibitor test. A high concentration of the MC7
supernatant corresponds to a high percentage of ACE
inhibition (Fig. 2), thereby indicating that the MC7
supernatant contains metabolites that can inhibit ACE
activity. The IC50 of the MC7 supernatant and of
captopril was 263.098 ppm and 98.501 ppm,
respectively. Isolate MC7 is recommended as a
probiotic given its functional property as an ACE
inhibitor. The supernatant had inhibitor activity to ACE
with IC50 of 263.099 ppm, while captopril had IC50 of
98,501 ppm. This IC50 of MC7 supernatant was higher
than IC50 of captopril (98.501 ppm), thereby indicating
that the inhibitor activity of isolate MC7 against ACE
was lower than that of captopril. Captopril contains pure
compounds, while the MC7 supernatant contains
mixture compounds. The MC7 supernatant can inhibit
ACE although the supernatant was not concentrated yet.
Therefore, the MC7 supernatant needs to be extracted to
increase its inhibitor activity against ACE. For example,
after extraction and fractionation of fraction 27 of L.
sakei CRL 1862 and fraction 30 of L. curvatus CRL
705, two lactic acid bacteria were isolated from
traditional sausage; they have the active peptide
FISNHAY and exhibit inhibitor activity of 54±2.3% and
50±3.1%, respectively, agaist ACE [6].
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-glucosidase inhibitor test. The MC1, MC7, and
MA15 isolates and the control had weak ɑ-glucosidase
inhibitor activity. Acarbose had the strongest ɑglucosidase inhibitor activity, while the supernatant
MC7 isolate had weak ɑ-glucosidase inhibitor activity
(Fig.2). The inhibitor activity of supernatant MC7
ranges from 0.58% to 3.55%. In this research, the
supernatant of isolate MC7 was a weak inhibitor against
ɑ-glucosidase activity. This condition is probably caused
by the fact that the supernatant of isolates was not
concentrated yet. The supernatant can be extracted with
organic solvent to separate the compounds that have
inhibitory activity against ɑ-glucosidase. Lactobacillus
rhamnosus Z7 (isolated from human feces) has been
recommended as a probiotic with a functional property
as inhibitor of ɑ-glucosidase. The supernatant of the
bacteria can inhibit ɑ-glucosidase with a percentage of
29.21 ± 0.99 % [7]. The inhibitor activity of L.
rhamnosus Z7 supernatant against ɑ-glucosidase was
almost equal to that of inhibitor of commercial
probiotic, i.e. L. rhamnosus GG ATCC 53103 (Valio
Ltd., Helsinki, Finland), which has inhibitor activity
against ɑ-glucosidase of 29.57 ± 1.38% [7].

Conclusion
Isolate MC7 is closely related to Lactobacillus
rhamnosus, and isolates MC1 and MA15 are closely
related to Enterococcus durans. The isolates MC1 and
MA15 can be recommended as probiotics, but their
hemolytic activity needs further investigation to
determine if they are not pathogenic. The isolates MC1
and MA15 are weak inhibitors against ACE and ɑglucosidase. Isolate MC7 exhibited inhibitor activity
against ACE with IC50 263.099 ppm, but it weakly
inhibited ɑ-glucosidase. Isolate MC7 is recommended
as a probiotic with a functional property as inhibitor of
ACE. This research has some limitations and can be
expanded in different aspects, such as the extraction of
bioactive compounds and the determination of bioactive
compounds and bile salt hydrolase activity.
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